Intervention Review

You have free access to this content

Temozolomide for high grade glioma

  1. Michael G Hart1,*,
  2. Ruth Garside2,
  3. Gabriel Rogers3,
  4. Ken Stein4,
  5. Robin Grant5

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 30 APR 2013

Assessed as up-to-date: 6 MAR 2013

DOI: 10.1002/14651858.CD007415.pub2


How to Cite

Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD007415. DOI: 10.1002/14651858.CD007415.pub2.

Author Information

  1. 1

    Department of Neurosurgery, Academic Division of Neurosurgery, Department of Clinical Neurosciences, Cambridge, UK

  2. 2

    University of Exeter Medical School, University of Exeter, European Centre for Environment and Human Health, Truro, UK

  3. 3

    National Institute for Health and Clinical Excellence, Centre for Clinical Practice, Manchester, UK

  4. 4

    University of Exeter Medical School, University of Exeter, Peninsula Technology Assessment Group (PenTAG), Exeter, UK

  5. 5

    Western General Hospital, Edinburgh Centre for Neuro-Oncology (ECNO), Edinburgh, Scotland, UK

*Michael G Hart, Academic Division of Neurosurgery, Department of Clinical Neurosciences, Department of Neurosurgery, Box 167, Addenbrookes Hospital, Cambridge, CB2 0QQ, UK. mikehart82@me.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram: search strategy update 2007 - 2012
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 4]
Figure 4. Funnel plot of comparison: 2 Recurrence Therapy, outcome: 2.1 Survival.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Primary Concomitant/Adjuvant Therapy, Outcome 1 Overall survival.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Primary Concomitant/Adjuvant Therapy, Outcome 2 Progression-free survival.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Primary Concomitant/Adjuvant Therapy, Outcome 3 Adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 1 Survival (temozolomide alone versus hypofractionated radiotherapy) alone.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 2 Survival (temozolomide alone versus standard radiotherapy alone).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 3 Progression free survival (temozolomide alone versus standard radiotherapy alone).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 4 Adverse Events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Different temozolomide dosing schedules, Outcome 1 Survival.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Different temozolomide dosing schedules, Outcome 2 Adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Therapy for recurrent disease, Outcome 1 Survival.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Therapy for recurrent disease, Outcome 2 Progression-Free Survival.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Therapy for recurrent disease, Outcome 3 Adverse events.